CJC-1295

WELL RESEARCHED

Short-acting growth hormone releasing hormone analog | Modified GRF 1-29

Typical dose
100-300 mcg
2-3 times a day
Route
Injectable
Subcutaneous: belly, thigh or arm
Cycle
12-16 weeks
Typical duration
Storage
2-8 °C
Refrigerated

Overview

What is CJC-1295?

CJC-1295 without DAC, also known as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body's natural GH secretion patterns. Unlike the DAC-modified version, it has a short half-life of about 30 minutes, allowing more precise control over GH pulses and reducing the risk of receptor desensitization.

Key benefits

Preserves natural GH pulsatility, minimal side effects, no receptor desensitization and precise control over GH release.

Mechanism of action

It binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses.

Quick start guide

Typical dose
100 mcg (10 units if reconstituted at 100 mcg/10 units)
How often
2-3 times a day for pulsatile release
Where to inject
Subcutaneous: lower belly (5 cm from the navel), outer thigh or back of the arm
Injection timing
Morning (on waking), post-workout (if applicable) and 30 minutes before bed
Effects timeline
GH elevation in 30 minutes; IGF-1 increase in 2-4 weeks; body composition changes in 6-12 weeks
Storage
Refrigerate immediately, use within 30 days after reconstitution
Cycle length
12-16 weeks of continuous use
Break between
Optional 2-4 week breaks to assess baseline

What to expect

Side effects & safety

Frequently asked questions

What is CJC-1295?

CJC-1295 (without DAC), also called Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates pulsatile GH release.

What is CJC-1295 researched for?

It is studied for growth hormone stimulation, recovery and body composition.

How does CJC-1295 work?

It binds to GHRH receptors on the pituitary's somatotroph cells and triggers GH release in physiological pulses.

How long does CJC-1295 take to work?

GH elevation occurs in about 30 minutes, IGF-1 increase in 2-4 weeks and body composition changes in 6-12 weeks.

What is the usual CJC-1295 dose?

In the without-DAC version, around 100 mcg, 2-3 times a day. The schedule is set by a professional.

How is CJC-1295 administered?

Subcutaneously; usually in the morning, after training and before bed.

How is CJC-1295 stored?

Refrigerated, using it within 30 days after reconstitution. See the storage guide.

What are the side effects of CJC-1295?

Usually well tolerated; temporary facial flushing may appear after injection.

Which peptides is CJC-1295 combined with?

The most popular combination is CJC-1295 with Ipamorelin, which boosts GH release.

What is the difference between CJC-1295 with and without DAC?

The DAC version has a very long half-life; the version without DAC lasts about 30 minutes, which is more physiological and controllable.

Is CJC-1295 approved?

It is not FDA-approved for human use.

Research areas

Related peptides

Related articles

Related topics

Summary

What it is: GHRH analog (Mod GRF 1-29) without DAC.

How it is researched: Subcutaneous, ~100 mcg, 2-3 times a day.

Key features: Releases GH in physiological pulses; short half-life. Not FDA-approved.

Related peptides: Ipamorelin, Sermorelin and Tesamorelin.